Loading stock data…
PODD
$167.53-3.86 (-2.25%)
Pre-Market$181.01+13.48 (+8.05%)· Last close May 5
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Insulet Corporation in the Healthcare sector is trading at $167.53. The stock is currently near its 52-week low of $158.35, remaining 40.4% below its 200-day moving average. Technical signals show oversold RSI of 26 and bearish MACD signal, explaining why PODD maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 26) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$167.53
Potential Downside
61.9%
Whystock Fair Value$63.77
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus23 analysts
Buy
Mean target$326.35+94.8%
Range$220.00 – $435.00
Fundamentals
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin de...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.63B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
55.48
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.58%
Volume
Today's trading volume
1.46M
Recent News
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of +25.93% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why
Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.
Insulet (PODD) Upgraded to Buy: Here's Why
Insulet (PODD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Insulet (PODD) Is Down 7.7% After FDA Class I Omnipod 5 Recall Expansion - And What's Next
In recent weeks, Insulet has expanded a voluntary Medical Device Correction and faced an FDA Class I recall of certain Omnipod 5 insulin pump pods after identifying a defect that could cause insulin under-delivery and serious safety risks. The company is working with regulators to clarify that hundreds of serious injury reports reflect potential, not all confirmed, adverse events while it adds affected lots, a process that may weigh on clinician confidence and product perceptions. Next,...
Rothschild & Co Redburn Downgrades Insulet Corporation (PODD), Cites “Eroding” Product Moats and Distribution
Insulet Corporation (NASDAQ:PODD) is one of the best medical device stocks to invest in right now. On April 24, Insulet Corporation (NASDAQ:PODD) was downgraded to Neutral from Buy by Rothschild & Co Redburn, with the firm bringing the price target on the stock down to $220 from $380. It told investors in a research note […]